Legacy Healthcare
Tetiana Rossetti has a background in clinical operations and management, with extensive experience in overseeing clinical trials and programs. With a strong track record in building and leading fit-for-purpose clinical operations teams, Tetiana has worked in various roles in companies such as Legacy Healthcare, ObsEva SA, and Quintiles. Tetiana's expertise includes driving clinical program deliverables, managing clinical service providers and sites, overseeing regulatory compliance, and collaborating with cross-functional teams. With a Master's degree in Pharmacy from Zaporizhzhia State Medical University, Tetiana brings a wealth of knowledge and experience to their role as Head of Clinical Operations at Legacy Healthcare.
This person is not in any teams
Legacy Healthcare
Legacy Healthcare aims to develop novel drugs for autoimmune, inflammatory and aging-related conditions, safe enough for chronic use especially by fragile population, e.g. children, cancer patients and the elderly, who may be already on multiple medications. Our first drug, Coacillium, is currently in Phase II/III testing for the treatment of Alopecia Areata, a debilitating scalp condition with intense medical and psychological impact on all patients, especially in children, and their families. Coacillium’s safety profile is without equal. For this reason health authorities have taken the unusual step of authorizing testing in children (starting at age 2) before adult testing. We expect Coacillium to be approved by 2023, as the first drug for Pediatric Alopecia Areata.